• What Happened: A $10 antiparasitic pill is showing real anti-cancer results in peer-reviewed clinical trials at Johns Hopkins.
  • Why It Matters: It's off-patent. No one can monopolize it. So no one is funding the trials that would make it standard of care.
  • Bottom Line: Two Johns Hopkins patients have been on it for five years. You've never heard of it. Ask why.

It started the way a lot of medical breakthroughs do. By accident.

In 2011, researchers at Johns Hopkins were studying antiparasitic compounds when they made a discovery that had nothing to do with their original research: mice with glioblastoma, the deadliest form of brain cancer, lived 63 percent longer when treated with mebendazole, a drug that has been safely deworming humans since 1971. A pill that costs less than a cup of coffee was outperforming established cancer treatments in the lab.

What followed was more than a decade of quietly extraordinary research that most Americans have never heard about.

Johns Hopkins launched a formal Phase 1 clinical trial in 2013. Twenty-four patients with newly diagnosed high-grade gliomas received mebendazole alongside standard chemotherapy. The trial ran for six years. Two patients are still on mebendazole today, more than five years later, with no severe adverse events attributable to the drug. The safety record was so clean that researchers concluded high-dose mebendazole in combination with standard treatment was well tolerated and warranted further investigation.

The science behind it is not mysterious. Mebendazole works by binding to a protein called beta-tubulin, essentially jamming the machinery that cancer cells use to divide and spread. It blocks tumor blood vessel formation, starving growths of the oxygen they need to survive. It targets cancer stem cells, the treatment-resistant seeds responsible for the recurrences that kill patients after initial treatment appears to work. And critically, it crosses the blood-brain barrier, a wall that defeats most cancer drugs before they even reach the tumor.

Published research shows promise across glioblastoma, medulloblastoma, meningioma, colon cancer, breast cancer, lung cancer, and prostate cancer. A 2021 Johns Hopkins patent formalized a specific polymorph of the drug optimized for tumor treatment. International trials are ongoing.

So why has virtually no one heard of this?

The answer is not complicated. Mebendazole is off-patent. Any manufacturer can make it. No single pharmaceutical company can own it, price it at $100,000 a year, or recoup the billion-dollar investment required to run the Phase 3 trials that would make it a standard of care. The cancer treatment industry generates over $200 billion annually on designer drugs developed and priced specifically to maximize shareholder returns. A $10 pill that cannot be monopolized is not a product. It is a problem.

The research is not suppressed. It is published in peer-reviewed journals, registered on ClinicalTrials.gov, and conducted openly at some of the most respected medical institutions in the world. It is simply underfunded, under-prioritized, and almost entirely invisible to the patients who need it most.

Two patients from Johns Hopkins' own trial have been alive and on mebendazole for over five years. Glioblastoma's median survival without treatment is fifteen months.

That is not a conspiracy theory. That is a math problem. And the American cancer patient is the one paying for it.